Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Prodrug
Dasolampanel
Другие языки:

    Dasolampanel

    Подписчиков: 0, рейтинг: 0
    Dasolampanel
    Dasolampanel.svg
    Clinical data
    ATC code
    • None
    Identifiers
    • (3S,4aS,6S,8aR)-6-(3-Chloro-2-(1H-tetrazol-5-yl)phenoxy)decahydroisoquinoline-3-carboxylic acid
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C17H20ClN5O3
    Molar mass 377.83 g·mol−1
    3D model (JSmol)
    • c1cc(c(c(c1)Cl)c2[nH]nnn2)O[C@H]3CC[C@H]4CN[C@@H](C[C@H]4C3)C(=O)O
    • InChI=1S/C17H20ClN5O3/c18-12-2-1-3-14(15(12)16-20-22-23-21-16)26-11-5-4-9-8-19-13(17(24)25)7-10(9)6-11/h1-3,9-11,13,19H,4-8H2,(H,24,25)(H,20,21,22,23)/t9-,10+,11-,13-/m0/s1
    • Key:LAKQPSQCICNZII-NOHGZBONSA-N

    Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, but ultimately neither drug was ever marketed.

    See also



    Новое сообщение